Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation

Debra Lynch Kelly, David Buchbinder, Rafael F. Duarte, Jeffrey J. Auletta, Neel Bhatt, Michael Byrne, Zachariah DeFilipp, Melissa Gabriel, Anuj Mahindra, Maxim Norkin, Helene Schoemans, Ami J. Shah, Ibrahim Ahmed, Yoshiko Atsuta, Grzegorz W. Basak, Sara Beattie, Sita Bhella, Christopher Bredeson, Nancy Bunin, Jignesh DalalAndrew Daly, James Gajewski, Robert Peter Gale, John Galvin, Mehdi Hamadani, Robert J. Hayashi, Kehinde Adekola, Jason Law, Catherine J. Lee, Jane Liesveld, Adriana K. Malone, Arnon Nagler, Seema Naik, Taiga Nishihori, Susan K. Parsons, Angela Scherwath, Hannah Lise Schofield, Robert Soiffer, Jeff Szer, Ida Twist, Anne Warwick, Baldeep M. Wirk, Jean Yi, Minoo Battiwalla, Mary E. Flowers, Bipin Savani, Bronwen E. Shaw

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Society for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT. In this review we define what constitutes neurocognitive dysfunction, characterize its risk factors and sequelae, describe tools and methods to assess neurocognitive function in HCT recipients, and discuss possible interventions for HCT patients with this condition. This review aims to help clinicians understand the scope of this health-related problem, highlight its impact on well-being of survivors, and help determine factors that may improve identification of patients at risk for declines in cognitive functioning after HCT. In particular, we review strategies for preventing and treating neurocognitive dysfunction in HCT patients. Finally, we highlight the need for well-designed studies to develop and test interventions aimed at preventing and improving neurocognitive dysfunction and its sequelae after HCT.

Original languageEnglish (US)
Pages (from-to)228-241
Number of pages14
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number2
DOIs
StatePublished - Feb 2018

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Kelly, D. L., Buchbinder, D., Duarte, R. F., Auletta, J. J., Bhatt, N., Byrne, M., DeFilipp, Z., Gabriel, M., Mahindra, A., Norkin, M., Schoemans, H., Shah, A. J., Ahmed, I., Atsuta, Y., Basak, G. W., Beattie, S., Bhella, S., Bredeson, C., Bunin, N., ... Shaw, B. E. (2018). Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 24(2), 228-241. https://doi.org/10.1016/j.bbmt.2017.09.004